학술논문
Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD Medications.
Document Type
Article
Author
Sima, Ali Reza; Saberzadeh-Ardestani, Bahar; Vahedi, Homayoon; Fakheri, Hafez; Mansour-Ghanaei, Fariborz; Maleki, Iradj; Nasseri-Moghaddam, Siavosh; Vosoghinia, Hasan; Ghadir, Mohammad Reza; Hormati, Ahmad; Kasaeian, Amir; Radmard, Amir Reza; Khosravi, Bardia; Malekzadeh, Masoud; Alatab, Sudabeh; Sadeghi, Anahita; Aminisani, Nayyereh; Poustchi, Hossein; Gonoudi, Elnaz; Anushiravani, Amir
Source
Subject
*EVALUATION of medical care
*COVID-19
*INFLAMMATORY bowel diseases
*CONFIDENCE intervals
*AGE distribution
*FAMILIES
*TREATMENT effectiveness
*SYMPTOMS
*DESCRIPTIVE statistics
*HOSPITAL care
*TUMOR necrosis factors
*LOGISTIC regression analysis
*ODDS ratio
*LONGITUDINAL method
*MESALAMINE
*EVALUATION
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1029-2977
Abstract
Background: Most data on the effect of inflammatory bowel disease (IBD) and its treatments on coronavirus disease 2019 (COVID-19) outcomes have not had non-IBD comparators. Hence, we aimed to describe COVID-19 outcomes in IBD compared to non-IBD patients. Methods: We conducted a prospective cohort study of registered IBD patients with confirmed COVID-19 from six provinces in Iran from February to April 2020. Proven COVID-19 patients were followed up at four weeks and the frequency of outcomes was assessed. Multivariable logistic regression was used to assess associations between demographics, clinical characteristics and COVID-19 outcomes. Results: Overall, 2159 IBD patients and 4721 household members were enrolled, with 84 (3.9%) and 49 (1.1%) participants having confirmed COVID-19, respectively. Household spread of COVID-19 was not common in this cohort (1.2%). While hospitalization was significantly more frequent in IBD patients compared with non-IBD household members (27.1% vs. 6.0%, P = 0.002), there was no significant difference in the frequency of severe cases. Age and presence of IBD were positively associated with hospitalization in IBD compared with non-IBD household members (OR: 1.06, 95% CI: 1.03-1.10; OR: 5.7, 95% CI: 2.0216.07, respectively). Age, presence of new gastrointestinal symptoms, and 5-aminosalicylic acid (5-ASA) use were associated with higher hospitalization rate in IBD patients (OR: 1.13, 95% CI: 1.05-1.23; OR: 6.49, 95% CI: 1.87-22.54; OR: 6.22, 95% CI: 1.90-20.36, respectively). Anti-tumor necrosis factor (TNF) was not associated with more severe outcomes. Conclusion: Age, presence of new gastrointestinal symptoms and use of 5-ASA were associated with increased hospitalization rate among IBD patients, while anti-TNF therapy had no statistical association. [ABSTRACT FROM AUTHOR]